More Adolescents and Young Adults Enrolled in Trials After Launch of NCTN
TUESDAY, Sept. 13, 2022 (HealthDay News) — The proportion of adolescents and young adults (AYAs; aged 15 to 39 years) enrolled in clinical trials increased after launch of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) in…
Learn MoreScreening Test Leads to Fewer Women Included in Autism Studies
MONDAY, Sept. 12, 2022 (HealthDay News) — A frequently used screening test for autism creates a gender gap that could hinder diagnosis and treatment for women and girls, a new study suggests.Researchers who study autism have been working to include m…
Learn MoreUn medicamento experimental se muestra promisorio contra el lupus
JUEVES, 8 de septiembre de 2022 (HealthDay News) — Un medicamento experimental, que se ha demostrado que puede tratar los sarpullidos en las personas con lupus, también podría ayudar con el dolor de las articulaciones relacionados con el lupus.El lup…
Learn MoreExperimental Drug Shows Promise Against Lupus
THURSDAY, Sept. 8, 2022 (HealthDay News) — An experimental drug that has been shown to treat rashes in people with lupus may also help with lupus-related joint pain.Affecting as many as 1.5 million people in the United States, lupus is an autoimmune …
Learn MoreExperimental Drug Shows Promise Against Lupus
THURSDAY, Sept. 8, 2022 (HealthDay News) — An experimental drug that has been shown to treat rashes in people with lupus may also help with lupus-related joint pain.Affecting as many as 1.5 million people in the United States, lupus is an autoimmune …
Learn MoreUn nuevo tratamiento para la EM se muestra promisorio en un ensayo
JUEVES, 25 de agosto de 2022 (HealthDay News) — Una terapia experimental de anticuerpos para la esclerosis múltiple (EM) puede reducir las exacerbaciones de síntomas a la mitad, en comparación con el tratamiento estándar, encontró un nuevo ensayo clí…
Learn MoreNew MS Treatment Shows Promise in Trial
THURSDAY, Aug. 25, 2022 (HealthDay News) — An experimental antibody therapy for multiple sclerosis can cut symptom flare-ups by half, versus a standard treatment, a new clinical trial has found.The drug, called ublituximab, beat a standard oral medic…
Learn MorePill to Counter Lupus Shows Promise in Mouse Study
THURSDAY, Aug. 25, 2022 (HealthDay News) — An experimental new pill could boost treatment of the autoimmune disease lupus, researchers reported at the American Chemical Society’s annual meeting.The pill has been shown in mouse studies to inhibit lupu…
Learn MoreNIH Trial Underway for Universal Flu Vaccine
WEDNESDAY, July 13, 2022 (HealthDay News) — The National Institutes of Health Clinical Center has begun a phase I trial of a potential universal influenza vaccine, according to an announcement by the agency.The National Institute of Allergy and Infec…
Learn More